Skip to main content
SpringerLink
Log in

Susceptibility ofHaemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite

  • Letters
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Neu HC The development of macrolides: clarithromycin in perspective. Journal of Antimicrobial Chemotherapy 1991, 27, Supplement A: 1–9.

    Google Scholar 

  2. Fernandes PB, Ramer N, Rode RA, Freiberg L Bioassay for A-56268 (TE-031) and identification of its major metabolite 14-hydroxy-6-0-methyl erythromycin. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 73–76.

    Google Scholar 

  3. Dabernat H, Delmas G, Seguy M, Fourtillan JB, Girault J, Lareng MB The activity of clarithromycin and its 14-hydroxy metabolite againstHaemophilus influenzae, determined by in vitro and serum bactericidal tests. Journal of Antimicrobial Chemotherapy 1991, 27, Supplement A: 19–30.

    PubMed  Google Scholar 

  4. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ Enhancement of the in vitro and in vivo activities of clarithromycin againstHaemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrobial Agents and Chemotherapy 1990, 34: 1407–1413.

    PubMed  Google Scholar 

  5. Logan MN, Ashby JP, Andrews JM, Wise R The in vitro activity and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite. Journal of Antimicrobial Chemotherapy 1991, 27: 161–170.

    PubMed  Google Scholar 

  6. Powell M, Chen HY, Weinhardt B, Williams JD In vitro activity of clarithromycin and its 14-hydroxy metabolite (A-62671) againstHaemophilus influenzae. Journal of Antimicrobial Chemotherapy 1991, 27: 694–696.

    PubMed  Google Scholar 

  7. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A4 (4th edition). NCCLS, Villanova, PA, 1990.

    Google Scholar 

  8. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2 (2nd edition). NCCLS, Villanova, PA, 1990.

    Google Scholar 

  9. Barry AL, Fernandes PB, Jorgensen JH, Thornsberry G, Hardy DJ, Jones RN Variability of clarithromycin and erythromycin susceptibility tests withHaemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. Journal of Clinical Microbiology 1988, 26: 2415–2420.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Clinical Microbiology Institute, P.O. Box 947, 97062, Tualatin, Oregon, USA

    A. L. Barry

  2. St. Vincent Hospital & Medical Center, 97225, Portland, Oregon, USA

    P. C. Fuchs

  3. Oregon Health Sciences University, 97201, Portland, Oregon, USA

    M. A. Pfaller

Authors
  1. A. L. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. C. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Pfaller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barry, A.L., Fuchs, P.C. & Pfaller, M.A. Susceptibility ofHaemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite. Eur. J. Clin. Microbiol. Infect. Dis. 10, 1080–1081 (1991). https://doi.org/10.1007/BF01984936

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01984936

Keywords

Search

Navigation